Chemoprevention of breast cancer: Implications for postmenopausal women

Drugs and Aging

Volumn 19, Issue 1, 2002, Pages 43-78

  Fabian, Carol J ^a,b   Kimler, Bruce F ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOLBIFENE; ALDOSTERONE RECEPTOR; ANASTROZOLE; AROMATASE; ARZOXIFENE; BEXAROTENE; CYCLOOXYGENASE 2; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; FENRETINIDE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; RALOXIFENE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN RECEPTOR; SULFATASE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

AGING; BONE DENSITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CARCINOMA IN SITU; CLINICAL TRIAL; DRUG INDICATION; ESTROGEN THERAPY; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT;

EID: 0036235246     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219010-00004     Document Type: Review

References (426)

1. Cancer statistics, 1999
2. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
3. Mechanistic considerations in chemopreventive drug development
4. Estrogens as a cause of human cancer: The Richard and Linda Rosenthal foundation award lecture
5. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer
6. American Society of Clinical Oncology technology assessment of breast cancer risk reduction strategies: Tamoxifen and raloxifene
7. Raloxifene: A selective estrogen receptor modulator
8. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
9. Therapeutic controversy - Estrogen replacement in menopause
10. Improved strategies for diagnosis and treatment of osteoporosis
11. Vertebrae fractures and mortality in older women: A prospective study of osteoporosis fracture research group
12. Hormone therapy to prevent disease and prolong life in postmenopausal women
13. Decreased mortality in users of estrogen replacement therapy
14. Effects of estrogen or estrogen/progesterone regimens on heart disease risk factors in postmenopausal women
15. Postmenopausal hormone therapy and mortality
16. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia?
17. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
18. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
19. Patient-specific decisions about hormone replacement therapy in postmenopausal women
20. Treatment of postmenopausal osteoporosis
21. Excess mortality attributable to hip fracture in white women aged 70 years and older
22. Hormone replacement therapy and cognition
23. Postmenopausal hormone therapy increases risk for venous thromboembolic disease
24. Design of the women's health initiative clinical trial and observational study
25. Postmenopausal hormone replacement therapy and breast cancer
26. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
27. Validation of a breast cancer risk assessment model in women with a positive family history
28. Graphs to estimate an individualized risk of breast cancer
29. Validation studies for models projecting the risk of invasive and total breast cancer incidence
30. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model
31. Breast cancer chemoprevention: Beyond tamoxifen
32. Women's beliefs and decisions about hormone replacement therapy
33. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
34. Models for early chemoprevention trials in breast cancer
35. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions
36. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials
37. Risk biomarkers and current strategies for cancer chemoprevention
38. Chemoprevention for high risk women: Tamoxifen and beyond
39. Alterations in DNA methylation: A fundamental aspect of neoplasia
40. Methylation and silencing of the retinoic acid receptor-B2 gene in breast cancer
41. Abnormal patterns of DNA methylation in human neoplasia: Potential consequences for tumor progression
42. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
43. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast
44. Balance of cell proliferation and apoptosis in breast carcinogenesis
45. Dysregulation of apoptosis in cancer
46. Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions: A marker for precancerous disease?
47. Immunohistochemical localization of integrins in the normal, hyperlastic and neoplastic breast: Correlations with their functions as receptors and cell adhesion molecules
48. Altered expression of a structural protein (fodrin) within epithelial proliferation disease of the breast
49. Development of breast cancer chemopreventive drugs
50. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci
51. Premalignant breast lesions: Role for biological markers in predicting progression to cancer
52. Intraepithelial and post-invasive neoplasia as a stochastic continuum of clonal evolution and its relationship to mechanisms of chemopreventive drug action
53. Breast cancer following benign breast disease: A nationwide study
54. Anatomic markers of human premalignancy and risk of breast cancer
55. Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer by more extensive disease
56. Lobular neoplasia (lobular carcinoma in situ)
57. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast
58. Morphofunctional features of intraductal hyperplasia, atypical intraductal hyperplasia, and various grades of intraductal carcinoma
59. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies
60. Precancerous and cancerous breast lesions during lifetime and at autopsy
61. Autopsy studies of the occurrence of cancerous, atypical and benign epithelial lesions in the female breast
62. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women
63. Estrogen and progesterone receptors in benign breast epithelium
64. The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol
65. Histological and biological evolution of human premalignant breast disease
66. Dissociation between steroid receptor expression and cell proliferation in the human breast
67. Neu-oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues
68. Differential expression of estrogen, progesterone and epidermal growth factor receptor in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry
69. Role of hormones in mammary cancer initiation and progression
70. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland
71. Hormonal approach to breast cancer prevention
72. Frequency and distribution of estrogen-receptor positive cells in normal non-lactating human breast tissue
73. Estrogen and progesterone receptors in the normal female breast
74. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle
75. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle
76. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast
77. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene
78. Autocrine and paracrine growth factors in the normal and the neoplastic breast
79. Transforming growth factor α in epithelial proliferative diseases of the breast
80. Role of the insulin-like growth factor family in cancer development and progression
81. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor
82. Dissociated over-expression of cathepsin D and estrogen receptor alpha in pre-invasive mammary tumors
83. Epidermal growth factor and amphirequlin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells
84. Insulin-like growth factor II modulates the routing of cathepsin D in MCF-7 breast cancer cells
85. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells
86. Expression of the HER-2/neu proto-oncogene in normal adult and fetal tissues
87. Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle
88. Recent developments of the biological role of progestins in human breast cancer
89. Mammary effects of progestins
90. Proliferating cell nuclear antigen in breast lesions: Correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer
91. Regulation of epidermal growth factor receptor by estrogen
92. Estrogen promotes chemotheraputic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells
93. Insulin-like growth factors in breast cancer
94. A correlative morphologic study of human breast and endometrium in the menstrual cycle
95. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas
96. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes
97. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells
98. BCL-2 expression in normal breast tissue during the menstrual cycle
99. Antagonism between estradiol and progestin on bcl-2 expression in breast cancer cells
100. The effect of age and menstrual cycle upon proliferative activity of the normal human breast
101. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors
102. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
103. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: A hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence
104. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma
105. Aromatase activity in normal breast and breast tumor tissues: In vivo and in vitro studies
106. Interleukin-1 and interleukin-6 in breast cyst fluid: Their role in regulating aromatase activity in breast cancer cells
107. Estrogen synthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP; leading to activation of promoter II CYP 19 (aromatase) gene
108. The potential of aromatase inhibitors in breast cancer prevention
109. Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions
110. Estrogen receptor expression of benign breast epithelium and its association with breast cancer
111. Expression of epidermal growth factor receptor mRNA and protein in primary breast cancers
112. Cathepsin D and epidermal growth factor in human breast cyst fluid
113. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue
114. Her-2/neu amplification in benign breast disease and the risk of subsequent breast cancer
115. Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression
116. Estrogen receptor-positive proliferating cells in the normal and precancerous breast
117. A hypersensitive estrogen receptor-α mutation in premalignant breast lesions
118. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients
119. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue
120. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
121. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
122. Cyclooxygenase-2 inhibitors in tumorogenesis, Part I
123. Expression of cyclo-oxygenase-1 and cyclo-oxygenase-2 in human breast cancer
124. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
125. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton
126. Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines
127. p53, the cellular gatekeeper for growth and division
128. Myc signalling via the ARF tumor suppressor regulates p53 dependent apoptosis and immortalization
129. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast
130. Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease
131. Loss of retinoic acid receptor B expression in breast cancer and normal adjacent tissue but not in normal tissue distinct from the cancer
132. Loss of p161NK4 expression of methylation is associated with lifespan extension of human mammary epithelial cells
133. Transforming growth factor-B and breast cancer risk in women with mammary epithelial hyperplasia
134. M6P/IGF2 receptor: A candidate breast tumor suppressor gene
135. Estrogen receptor expression in benign breast epithelium and breast cancer risk
136. Demethylation of the estrogen receptor gene in estrogen receptor: Negative breast cancer cells can reactivate estrogen receptor gene expression
137. Cell surface localization and density of the tumor associated variant of the epidermal growth factor receptor, EGFR VIII
138. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer
139. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
140. A sporadic amplification of the insulin-like growth factor I receptor gene in human breast tumors
141. Insulin-like growth factor-1 receptors are overexpressed and predict a low risk in human breast cancer
142. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo
143. Constitutive expression of insulin-like growth factor I and insulin-like growth factor I receptor abrogates all requirements for exogenous growth factors
144. Biomarkers in benign breast disease: Risk factors for breast cancer
145. p53 and c-erbB-2 protein expression in breast carcinomas: An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer
146. Differential ligand activation of estrogen receptors ER-α and ER-β at AP-1 sites
147. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis
148. Gene methylation of oestrogen and epidermal growth factor receptors in neoplastic and perineoplastic breast tissues
149. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
150. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer
151. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors alpha and beta
152. Estrogen receptors α and β form heterodimers on DNA
153. Estrogen, estrogen receptors and selective estrogen receptor modulators in human breast cancer
154. Nuclear receptor co-regulators: Cellular and molecular biology
155. Allosteric silencing of activating function I in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
156. Selective estrogen receptor modulators: Structure, function, and clinical use
157. The value of estrogen and progesterone receptors in the treatment of breast cancer
158. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer
159. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer
160. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
161. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer
162. Estrogens, progestrins, normal breast cell proliferation, and breast cancer risk
163. Hysterectomy, oophorectomy and premenopause, and risk of breast cancer
164. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
165. Medical hypothesis: Bifunctional genetic-hormonal pathways to breast cancer
166. Estrogen responsiveness and control of normal human breast proliferation
167. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer
168. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells
169. 17 Beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product
170. Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells
171. Bcl-2 family proteins and the hormonal control of cell life and death in normalcy and neoplasia
172. Programed cell death in human breast cancer cells
173. Expression and regulation of vascular endothelial growth factor in human breast cancer cells
174. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
175. Hormonal chemoprevention of cancer in women
176. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function
177. Association of age and reproductive factors with benign breast tissue composition
178. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation
179. Relationships between steroid receptor and epithelial cell proliferation in benign fibrocystic disease of the breast
180. Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue
181. Average annual rates of invasive and non-invasive breast cancer by history of LCIS and atypical hyperplasia for participants in the BCPT
182. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types
183. Breast cancer risk associated with proliferative disease, age at first live birth and a family history of breast cancer
184. Mammographic densities and breast cancer risk
185. Risk factors for breast cancer according to family history of breast cancer
186. Cigarette smoking, alcohol consumption and breast cancer risk
187. Alcohol intake and breast cancer risk: Effect of exposure from 15 years of age
188. Proportion of breast cancer cases in the United States explained by well established risk factors
189. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women
190. Effect of family history, body-fat distribution and reproductive factors on the risk of postmenopausal breast cancer
191. Diet, body size and breast cancer
192. Alcoholic beverage consumption in relation to risk of breast cancer: Meta-analysis and review
193. Nutritional regulation of the insulin-like growth factors
194. Breast cancer trends, incidence, mortality and survival
195. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention
196. Overview of the biology and management of ductal carcinoma in situ of the breast
197. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
198. Autosomal dominant inheritance of early-onset breast cancer
199. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history
200. Understanding mathematical models for breast cancer risk assessment and counseling
201. Population attributable risk for breast cancer: Diet, nutrition, and physical exercise
202. Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials
203. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy
204. Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk
205. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial
206. Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis
207. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer
208. Neoadjuvant arimidex or tamoxifen alone or combined for breast cancer (impact): PgR related reductions in proliferation marker Ki67
209. Correlative studies of the histological and radiographic appearance of the breast parenchyma
210. Mammographic densities as a criterion for entry to a clinical trial of breast cancer prevention
211. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: Results from a randomized trial
212. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
213. Effects of estrogen and estrogen-progestin on mammographic parenchymal density: Postmenopausal estrogen/progestin interventions (PEPI) investigators
214. Mammographic patterns as a predictive biomarker of breast cancer risk: Effect of tamoxifen
215. Insulin-like growth-factor-binding protein 3 is decreased in early stage operable pre-menopausal breast cancer
216. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
217. Mammographic features and breast cancer risk: Effects with time, age and menopause status
218. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density
219. Tamoxifen and mammographic breast densities
220. Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa women's health study
221. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
222. Low biologic aggressiveness in women using hormone replacement therapy
223. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States
224. Hormone replacement therapy and breast cancer mortality in Swedish women: Results after adjustment for 'healthy drug-user' effect
225. Estrogen replacement therapy and breast cancer survival in a large screening study
226. Use of HRT and the subsequent risk of cancer
227. Effect of acute ethanol ingestion on prolactin in menopausal women using estradiol replacement
228. Effects of alcohol ingestion on estrogens in postmenopausal women
229. Prospective study of relative weight and risk of breast cancer: The breast cancer detection demonstration project follow-up study 1979 to 1987-1989
230. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer
231. Suppression of aromatase (estrogen synthetase) by red wine phytochemicals
232. Alcohol and breast cancer in women: A pooled analysis of cohort studies
233. Insulin-like growth factor-1: A key regulator of human cancer risk?
234. Hormonal response to overfeeding
235. Proliferative activity of murine mammary epithelium as effected by dietary fat and calcium
236. Effects of dietary fat on tumorigenesis in the mouse mammary gland
237. Association of dietary intake of fat and fatty acids with risk of breast cancer
238. Future possibilities in the prevention of breast cancer: Fat and fiber and breast cancer research
239. William L. McGuire memorial symposium: 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo
240. 19-Nor-hexafluoride analogue of vitamin D3: A novel class of potent inhibitors of proliferation of human breast cell lines
241. 1α,25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells
242. Dietary folate consumption and breast cancer risk
243. A prospective study of folate intake and the risk of breast cancer
244. Dietary effects on breast cancer in Singapore
245. Epidemiology of phytoestrogens
246. Estrogenic effects of genistein in the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo
247. Exposure to flaxseed or its ligman component during different developmental stages influences rat mammary gland structures
248. Decreased ovarian hormones during a soya diet: Implications for breast cancer prevention
249. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women
250. Soy isoflavones exert modest hormonal effects in premenopausal women
251. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women
252. Soy consumption alters endogenous estrogen metabolism in postmenopausal women
253. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
254. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta
255. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein
256. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal breast
257. Retinoic acid receptor alpha 1 isoform is induced by estradiol and confers retinoic acid sensitivity in human breast cancer cells
258. Influence of drinking green tea on breast cancer malignancy among Japanese patients
259. Chemoprotection: A review of the potential therapeutic antioxidant properties of green tea (Camellia sinensis) and certain of its constituents
260. Association of coffee, green tea and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women
261. A prospective study of recreational physical activity and breast cancer risk
262. Lifetime exercise activity and breast cancer risk among postmenopausal women
263. Adiposity as a risk determinant for postmenopausal breast cancer
264. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
265. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2
266. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm breast cancer study group
267. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial: The Scottish cancer trials breast group
268. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial
269. The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
270. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
271. Tamoxifen decreases lipoprotein (a) in patients with breast cancer
272. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen
273. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptionmetry in healthy premenopausal and postmenopausal women
274. Estrogen, selective estrogen receptor modulation, and coronary heart disease: Something or nothing
275. Tamoxifen for early breast cancer: An overview of the randomized trials
276. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women
277. Antithrombin III level, fibrinogen level and platelet count change with adjuvant tamoxifen therapy
278. The effect of tamoxifen and hormone replacement in serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised controlled tamoxifen prevention study
279. Biologic activity of tamoxifen at low doses in healthy women
280. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1
281. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women
282. Decision analysis of tamoxifen for the prevention of breast cancer
283. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
284. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
285. The Italian breast cancer prevention trial with tamoxifen: Findings and new perspectives
286. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials
287. The Royal Marsden Hospital (RMH) trial: Key points and remaining questions
288. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
289. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
290. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
291. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study: Hereditary breast cancer clinical study group
292. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
293. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
294. Tamoxifen: Too much of a good thing?
295. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
296. Phase II evaluation of LY156758 in metastatic breast cancer
297. Raloxifene HCl, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer
298. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial: Multiple outcomes of raloxifene evaluation (MORE) investigators
299. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
300. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
301. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator in women with regular menstrual cycles
302. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
303. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice
304. LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo
305. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer
306. Efficacy and safety of two doses of the selective estrogen receptor modulator (Senn) Ly353381 in locally advanced or metastatic breast cancer (LAMBC): A randomized double blind phase 2 study
307. Phase I biomarker and toxicity evaluation of LY353381 (a 3rd generation selective estrogen receptor modulator, SERM) in breast cancer
308. A new antiestrogen, 2-(4-hydroxy-phenyl) -3-methyl- 1 -[4-(2-piperidin1-yl-ethoxy)-benzyl]- 1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats
309. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer
310. Coexpression of estrogen receptor α and β: Poor prognostic factors in human breast cancer?
311. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence
312. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors
313. Steroid receptor coactivator-1 is a histone acetyltransferase
314. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
315. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor
316. A hypersensitive estrogen receptor α protein in premalignant breast lesions
317. BCAR1/p130Cas protein and primary breast cancer: Prognosis and response to tamoxifen treatment
318. Tamoxifen: Toxicities and drug resistance during the treatment and prevention of breast cancer
319. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
320. Synergy of demethylation of histone deacetylase inhibition in the re-expression of genes silenced in cancer
321. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
322. Expression of estrogen receptor-beta in human breast tumors
323. William L. McGuire memorial lecture: Antiestrogens: Mechanisms of action and resistance in breast cancer
324. Tamoxifen activation of the estrogen receptor AP-1 pathway: Potential origin for the cellspecific estrogen like effects of anti-estrogens
325. Estrogen receptor β - A novel receptor opens up new possibilities for cancer diagnosis and treatment
326. Nuclear receptor coactivators and corepressors
327. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity
328. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
329. A double-blind randomized trial comparing the efficacy and tolerability of Faslodex™ (fulvestrant) with Arimidex™ in postmenopausal women with advanced breast cancer
330. Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer
331. New endocrine agents
332. Comparison of efficacy and tolerability of fulvestrant (Faslodex™) with anastrazole (Arimidex™) in postmenopausal women with advanced breast cancer (LABC preliminary results)
333. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
334. A partially-blind, randomised, multicentre study comparing the anti-tumor effects of single doses (50, 125, and 250 mg) of long-acting (LA) 'faslodex' (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer prior to surgery
335. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
336. Lessons from the use of aromatase inhibitors in the neoadjuvant setting
337. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
338. Study of the biological effects of the aromatase inhibitor letrozole in healthy postmenopausal women: Rationale for prevention
339. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
340. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
341. The ATAC (Arimidex, Tamoxifen, Alone, or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women
342. Recent advances in the development of steroid sulphatase inhibitors
343. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma
344. Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antiestrogens
345. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells
346. Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines
347. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand
348. Involvement of nuclear steroid/thyroid/retinoid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells
349. Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis
350. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells
351. Retinoids and apoptosis: Implications for cancer chemoprevention and therapy
352. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients
353. Chemoprevention of breast cancer with fenretinide (4-HPR): Study of longterm visual and ophthalmologic tolerability
354. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
355. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer
356. Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group
357. Effect of retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure
358. Retinoids and demethylating agents: Looking for partners
359. Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers
360. Prevention and therapy of mammary cancer by monoterpenes
361. Phase I clinical trial of perillyl alcohol administered daily
362. Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1alpha-hydroxyvitamin D5
363. Inhibition of insulin and insulin-like growth factor-1-stimulated growth of human breast cancer cells by 1, 25 dihydroxy-vitamin D3 and the vitamin D3 analogue EB 1089
364. Antiproliferative action of vitamin D related compounds and insulin-like growth factor binding protein-5 accumulation
365. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines
366. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
367. The effect of tamoxifen on benign breast disease. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT)
368. Protective effects of estrogen on the cardiovascular system
369. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): A randomized controlled trial
370. Estrogen and atherosclerosis
371. A controlled trial of raloxifene HCI: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
372. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial
373. Transdermal estradiol/norethisterone: A review of its pharmacologic properties and clinical use in postmenopausal women
374. Risk of venous thromboembolism in use of hormone replacement therapy
375. Venous thromboembolic events associated with hormone replacement therapy
376. Alternatives to estrogen for menopausal women
377. Prospective study of exogenous hormones and risk of pulmonary embolism in women
378. A meta-analysis of hormone replacement therapy and colon cancer in women
379. Estrogen actions in the central nervous system
380. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
381. Estrogen replacement therapy and cognitive function in women without dementia
382. Cognitive function in postmenopausal women treated with raloxifene
383. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen
384. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: Early postmenopausal intervention cohort study group
385. Raloxifene and estrogen comparative bone-remodeling kinetics
386. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: Long-term follow-up of a Swedish cohort
387. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
388. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women
389. Use of hormone replacement therapy by postmenopausal women in the United States
390. Prior to estrogen replacement therapy, are users healthier than non users?
391. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States
392. Prescribing hormone replacement therapy for menopausal symptoms
393. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
394. Prognostic characteristics in breast cancers after hormone replacement therapy
395. Hormone replacement therapy and high S phase in breast cancer
396. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
397. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers
398. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer: National Cancer Institution of Canada clinical trials group breast cancer site group
399. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels
400. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study
401. Hormone replacement therapy after breast cancer
402. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
403. A randomized pilot study of HRT in breast cancer patients: The combined effects of tamoxifen and HRT on the endometrium
404. Tamoxifen therapy for breast cancer and endometrial cancer risk
405. Reducing the risk of breast cancer with tamoxifen in women at increased risk
406. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms
407. Effect of Bellergal Retard on climacteric complaints: A double-blind, placebo-controlled study
408. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
409. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial
410. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors
411. Transdermal clonidine for ameliorating tamoxifen induced hot flashes
412. The effect of dietary soy supplementation on hot flashes
413. Estrogen deficiency: In search of symptom control and sexuality
414. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer
415. A one year multicenter study of efficacy and safety of a continuous, low dose estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms of urogenital aging
416. Hormone replacement therapy as treatment of breast cancer -a phase II study of Org OD 14 (tibolone)
417. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: A comparison
418. Tibolone: Influences on markers of cardiovascular disease
419. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
420. The controversial endocrinology of the menopausal transition
421. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The alendronate phase III osteoporosis treatment study group
422. The role of calcitonin in the prevention of osteoporosis
423. Non-pharmacological modification of cardiac risk factors: Part 1
424. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
425. Multisystem biological and symptomatic toxicity of tamoxifen in postmenopausal women
426. Coronary heart disease mortality and adjuvant tamoxifen therapy